Duloxetine: A review of its use in the treatment of generalized anxiety disorder

CNS Drugs

Volumn 23, Issue 6, 2009, Pages 523-541

  Carter, Natalie J ^a   McCormack, Paul L ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ANTACID AGENT; ANTIARRHYTHMIC AGENT; BENZODIAZEPINE; DESIPRAMINE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FAMOTIDINE; FLECAINIDE; HYDROXYZINE; IMIPRAMINE; LORAZEPAM; MAGNESIUM DERIVATIVE; NORTRIPTYLINE; PAROXETINE; PHENOTHIAZINE; PREGABALIN; PROPAFENONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FUNCTIONAL DISEASE; GENERALIZED ANXIETY DISORDER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEPATITIS; HUMAN; HYPERHIDROSIS; JAUNDICE; LIBIDO DISORDER; LIVER FAILURE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; SUICIDE; SUICIDE ATTEMPT; SUSTAINED DRUG RELEASE; SYNCOPE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DATABASES, BIBLIOGRAPHIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; HUMANS; META-ANALYSIS AS TOPIC; THIOPHENES; TREATMENT OUTCOME;

EID: 66749129181     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923060-00006     Document Type: Review

References (71)

1. Kessler RC, DuPont RL, Berglund P, et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999 Dec; 156 (12): 1915-23
2. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001; 62 Suppl. 11: 53-8
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
4. Wittchen H-U. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16 (4): 162-71
5. Wittchen H-U, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 Suppl. 8: 24-34
6. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun; 62 (6): 593-602
7. Hoffman DL, Dukes EM, Wittchen H-U. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008; 25 (1): 72-90
8. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive- compulsive and post-traumatic stress disorders: first revision. World J Biol Psych 2008; 9 (4): 248-312
9. Eli Lilly Nederland BV. Cymbalta® 30 mg hard gastro-resistant capsules: EU prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/cymbalta/H-572-PI-en.pdf [Accessed 2009 Mar 25]
10. Eli Lilly and Company. Cymbalta® (duloxetine hydrochloride) delayed-released capsules for oral use: highlights of US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/022148lbl. pdf [Accessed 2009 Mar 25]
11. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 2007; 21 (7): 581-609
12. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25 (6): 871-80
13. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997 Dec; 340 (2-3): 249-58
14. Koch S, Hemrick-Luecke SK, Thompson LK, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003; 45 (7): 935-44
15. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993; 8 (1): 23-33
16. Katoh A, Eigyo M, Ishibashi C, et al. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. J Pharmacol Exp Ther 1995 Mar; 272 (3): 1067-75
17. Reneric J-P, Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 1998 Mar; 136 (2): 190-7
18. Iyengar S, Bymaster F, Wong D, et al. Efficacy of the selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain [abstract]. Pain Med 2002 Jun; 3 (2): 177
19. Turcotte JE, Debonnel G, de Montigny C, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001; 24 (5): 511-21
20. Chalon SA, Granier L-A, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology 2003; 28 (9): 1685-93
21. Vincent S, Bieck PR, Garland EM, et al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 2004 Jun; 109 (25): 3202-7
22. Chalon S, Bieck PR, Goldstein DJ, et al. The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition [letter]. Neuropsychopharmacology 2002; 26 (5): 698-701
23. Chalon S, Granier L-A, Vandenhende F. Duloxetine affects sleep architecture with antidepressant like pattern [abstract no. PII-65]. Clin Pharmacol Ther 2001 Feb; 69 (2): P49
24. Kluge M, Schussler P, Steiger A. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsycho-pharmacol 2007 Jul; 17 (8): 527-31
25. Zhang L, Chappell J, Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 2007 Mar; 49 (3): 146-53
26. Chan C, Yeo KP, Pan AX, et al. Duloxetine pharmaco-kinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006; 63 (3): 310-4
27. Skinner MH, Skerjanec A, Seger M, et al. The effect of food and bedtime administration on duloxetine pharmacokinetics [abstract no. PII-59]. Clin Pharmacol Ther 2000 Feb; 67 (2): 129
28. Suri A, Reddy S, Gonzales C, et al. Duloxetine pharmaco-kinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther 2005 Feb; 43 (2): 78-84
29. Granier L-A, Vandenhende F, de Suray J-M, et al. Safety and pharmacokinetics of duloxetine, a potential new antidepressant with serotonin and norepinephrine uptake inhibition [abstract no. P.1.043]. Eur Neuropsychopharmacol 1999 Sep; 9 Suppl. 5: S222
30. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003; 31 (9): 1142-50
31. Lobo ED, Loghin C, Knadler MP, et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy post-partum women. Clin Pharmacokinet 2008; 47 (2): 103-9
32. Sharma A, Goldberg MJ, Cerimele BJ, et al. Pharmaco-kinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000 Feb; 40 (2): 161-7
33. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25 (3): 182-9
34. Davidson JRT, Wittchen H-U, Llorca P-M, et al. Dulox-etine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008 Sep; 18 (9): 673-81
35. Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 2006 Apr; 185 (3): 395-9
36. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and nor-epinephrine. J Clin Psychopharmacol 2005 Apr; 25 (2): 132-40
37. Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007; 30 (5): 437-55
38. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005; 11 (12): 1475-93
39. Karpa KD, Cavanaugh JE, Lakoski JM. Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 2002; 8 (4): 361-76
40. Hunziker ME, Suehs BT, Bettinger TL, et al. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005 Aug; 27 (8): 1126-43
41. Gupta S, Nihalani N, Masand P. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry 2007; 19 (2): 125-32
42. Trivedi MH, Desaiah D, Ossanna MJ, et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of du-loxetine. Int Clin Psychopharmacol 2008 May; 23 (3): 161-9
43. European Medicines Agency. EMEA scientific discussion document: duloxetine [online]. Available from URL: http:// www.emea.europa.eu/humandocs/ PDFs/EPAR/cymbalta/ 19256704en6.pdf [Accessed 2009 Mar 25]
44. Antipsychotic Mellaril removed from market [online]. Available from URL: http://www.schizophrenia.com/ sznews/archives/001377.html [Accessed 2009 Apr 28]
45. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007; 9 (2): 100-7
46. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psy-chopharmacol 2007 May; 22 (3): 167-74
47. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009 Feb; 39 (2): 267-76
48. Hartford JT, Endicott J, Kornstein SG, et al. Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim Care Companion J Clin Psychiatry 2008; 10 (3): 197-204
49. Russell JM, Weisberg R, Fava M, et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2008; 25 (7): E1-11
50. Sheehan DV, Meyers AL, Prakash A, et al. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin 2008 Sep; 24 (9): 2457-66
51. Endicott J, Russell JM, Raskin J, et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry 2007; 68 (4): 518-24
52. Pollack MH, Kornstein SG, Spann ME, et al. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res 2008 Oct; 42 (14): 1176-84
53. Allgulander C, Nutt D, Detke M, et al. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psy-chopharmacol 2008 Jun; 22 (4): 417-25
54. Davidson J, Allgulander C, Pollack MH, et al. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol 2008 Aug; 23 (6): 519-26
55. European Medicines Agency. Assessment report for Cym-balta® [online]. Available from URL: http://www.emea. europa.eu/humandocs/PDFs/EPAR/cymbalta/ Cymbalta-H-572-II-27-AR.pdf [Accessed 2009 Mar 25]
56. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuro-psychopharmacol 2005 Jun; 8 (2): 293-302
57. Nutt DJ, Ballenger JC, Sheehan D, et al. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol 2002 Dec; 5 (4): 315-25
58. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 37-41
59. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001; 62 Suppl. 3: 22-34
60. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008; 69 Suppl. E1: 8-13
61. Storosum JG, van Zwieten BJ, van den Brink W, et al. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 2001 Aug; 158 (8): 1271-5
62. Khan A, Warner HA, Brown WA, et al. Symptom reduction and suicide risk in patients treated with placebo in anti-depressant clinical trials: an analysis of the Food and Drug Administration Database. Arch Gen Psychiatry 2000 Apr; 57 (4): 311-7
63. Hammad TA, Mosholder A, Boehm G. Incidence of suicide in randomized controlled trials of patients with major depressive disorder [abstract no. 308]. Pharmacoepidemiol Drug Saf 2003 Aug; 12 Suppl. 1: S156
64. Hammad TA, Laughren TP, Racoosin J, et al. Suicide rates in short-term randomized controlled trials of newer antide-pressants. J Clin Psychopharmacol 2006 Apr; 26 (2): 203-7
65. Hammad TA, Laughren TP, Racoosin J, et al. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006 Mar; 63 (3): 332-9
66. Acharya N, Rosen AS, Polzer JP. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006 Dec; 26 (6): 587-94
67. Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007 Jul; 164 (7): 1029-34
68. Ninan PT. Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry 2001; 62 Suppl. 19: 5-10
69. Mogotsi M, Kaminer D, Stein DJ. Quality of life in the anxiety disorders. Harv Rev Psychiatry 2000; 8 (6): 273-82
70. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry 2000 May; 157 (5): 669-82
71. Konnopka A, Leichsenring F, Leibing E, et al. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord 2009 Apr; 114 (1-3): 14-31